If you've been searching for Zepbound in Delhi, Noida, Greater Noida or anywhere in India, you've probably hit a wall. Pharmacies don't carry it. Online sellers offering it are unverified. And you've seen US celebrities and influencers talking about it for months. So what's actually going on, and what are your real options?

This page is written by Dr. Manuj Sondhi (MRCP UK), Senior Consultant Physician and Diabetologist at Nirvana Clinic, Greater Noida. It's the same answer I give patients in clinic every week.

Zepbound and Mounjaro Are The Same Drug

This is the single most important fact, and the one most patients aren't told clearly:

Both Zepbound and Mounjaro contain exactly the same active molecule — tirzepatide — manufactured by the same company (Eli Lilly), in the same factories, delivered through the same injection pen, producing the same biological effects on the GLP-1 and GIP hormone receptors.

The only differences are:

• The brand name on the label — "Zepbound" vs "Mounjaro"
• The official regulatory indication — Zepbound is approved by the US FDA specifically for chronic weight management in adults with obesity, while Mounjaro is approved for type 2 diabetes (and used off-label for weight loss)

That's it. Eli Lilly created the two brand names purely to market the same drug to two different patient populations (people with diabetes vs people focused on weight loss) and to navigate insurance coverage rules in the US. From a clinical and pharmacological standpoint, they are identical.

Why Zepbound Hasn't Launched in India

Eli Lilly received approval from India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), to launch Mounjaro for type 2 diabetes — and Mounjaro went on sale in India in March 2025. However, the application for the obesity-specific indication (which is what would be sold as Zepbound in India) is still under review by CDSCO and has not yet been approved.

There's no confirmed launch date. Industry sources have suggested that an obesity-indicated tirzepatide product could appear in India sometime in 2026 or 2027, but Eli Lilly has not made any official announcement.

Practically speaking, this regulatory distinction doesn't matter much for patients in India because:

Mounjaro Pricing in India vs Zepbound in the US

One of the surprising upsides of Mounjaro being the only available form of tirzepatide in India is the pricing. Eli Lilly priced Mounjaro for the Indian market at a fraction of US Zepbound prices.

Indian pricing is approximate and subject to change. Always verify current MRP at the time of purchase.

For an Indian patient, accessing tirzepatide (Mounjaro) is significantly more affordable than accessing Zepbound in the US — even before factoring in the cost of clinical supervision.

⛔ Avoid the Grey Market

• Cold-chain failure. Tirzepatide must be stored between 2–8°C until use. Imported pens transported through unrefrigerated couriers, customs holds, or grey-market intermediaries lose potency or become unsafe.
• Counterfeit risk. Several global health agencies have flagged counterfeit GLP-1 pens entering grey markets. You cannot verify what's inside an unbranded vial.
• No medical supervision. Tirzepatide has serious contraindications (medullary thyroid carcinoma, MEN-2, pancreatitis history) and side effects that need monitoring. Self-injecting without a doctor is dangerous.
• Customs seizure. Personal importation of unapproved drugs into India is restricted under the Drugs and Cosmetics Act. Packages can be seized.
• You're paying more for less safety. Grey-market prices are often higher than legitimate Mounjaro prices in India anyway.

The legitimate, safer, and cheaper path is to get Mounjaro prescribed by a qualified physician in India.

How to Get Tirzepatide Treatment in Delhi NCR Safely

If you live in Delhi, Noida, Greater Noida, Gurgaon or anywhere in NCR, here's the proper path:

Step 1 — Medical Eligibility Assessment

Tirzepatide isn't appropriate for everyone. A physician needs to verify your BMI, screen for contraindications (thyroid, pancreatic, gallbladder history), check current medications for interactions, and rule out any reason you shouldn't take it.

Step 2 — Baseline Investigations

Standard pre-treatment workup includes complete blood tests (LFT, KFT, thyroid panel, HbA1c, lipid profile, vitamin D and B12), an abdominal ultrasound to check for gallstones, and body composition analysis to track lean mass vs fat mass changes over time.

Step 3 — Prescription & Dose Titration

Mounjaro must be started at 2.5mg weekly and gradually escalated over 16–20 weeks to minimise nausea and other GI side effects. Dose increases happen monthly under physician supervision. Most patients reach a maintenance dose between 5mg and 10mg.

Step 4 — Ongoing Monitoring

Regular follow-ups every 2–4 weeks during titration, then monthly. Side-effect management, dose adjustments, blood test rechecks, and lifestyle / dietary support form the core of safe long-term treatment.

Mounjaro vs Other GLP-1 Options in India

Mounjaro is not the only weight-loss drug available in India. Here's how it compares:

Mounjaro (tirzepatide) currently produces the greatest average weight loss of any approved medication, which is why patients searching for "Zepbound in India" are usually best served by simply being prescribed Mounjaro. For patients who prefer semaglutide-based options or want a more affordable starting point, Wegovy and the new generic semaglutide options launched after the March 2026 patent expiry are also excellent choices.

Read the dedicated pages: Mounjaro for Weight Loss India · Wegovy India · Ozempic India 2026 Price Guide · Ozempic vs Mounjaro

Frequently Asked Questions